Skip to content

    IOL Chemicals

    IOLCP
    Healthcare·13 Nov 2025
    Management Summary

    IOL Chemicals delivered a solid Q2 FY26, with revenue growing 7.9% YoY to INR567.5 crores and EBITDA up 33.3% to INR64 crores, driven by volume recovery and cost efficiencies. PAT increased 56.7% to INR30 crores. The company experienced a temporary dip in sequential profitability due to elevated fuel costs, but expects normalization in Q3. Strategic focus remains on non-Ibuprofen APIs, paracetamol facility ramp-up, and diversification into regulated markets, with positive regulatory updates.

    Highlights

    5
    • Revenue from operations grew 7.9% YoY to INR567.5 crores.

    • EBITDA increased 33.3% to INR64 crores, with margins expanding 212 bps to 11.1%.

    • Profit after tax (PAT) grew 56.7% YoY to INR30 crores, with PAT margin improving to 5.2%.

    • Post-tax cash profit grew 31.1% YoY to INR51.5 crores.

    • EU GMP inspection concluded with no major observations, only recommendations.

    Concerns

    3
    • Sequential dip in profitability due to INR7-8 crores impact from elevated fuel costs following Punjab floods.

    • Subdued pricing in the Chemicals segment despite volume recovery.

    • High market competitiveness for Sitagliptin, hindering commercial production despite EDQM approval.

    What Changed1

    vs Q3 FY26

    Guidance items13 → 11 (-2)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue from Operations₹567.5 Cr+7.9%YoY
    2. 02EBITDA₹64 Cr+33.3%YoY
    3. 03EBITDA Margin11.1%
    4. 04PAT₹30 Cr+56.7%YoY
    5. 05PAT Margin5.2%

    Segment breakdown

    Pharma
    59% Share of Total Revenue (H1 FY26)
    Chemical
    41% Share of Total Revenue (H1 FY26)
    List

    Capital allocation

    3
    medium confidence
    CategoryHeadline
    Capex

    ₹150 crores

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Healthy liquidity mentioned qualitatively.

    Guidance & targets

    11
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    13-14%
    High
    Profitability
    Annual EBITDA Margin Increase
    1-2% increase
    High
    Profitability
    EBITDA Margin
    13-15%
    High
    Product Mix
    Pharma Product Mix (Ibuprofen vs. Other APIs)
    50% Ibuprofen and 50% other pharma products
    Medium
    Cost Efficiency
    Reduction in power and fuel costs
    INR5-6 crores reduction
    High
    Capacity Utilization
    Paracetamol facility utilization
    65%
    High
    Regulatory
    Land parcel regulatory approvals
    all approvals obtained
    High
    Revenue
    H2 FY26 Revenue Growth
    10-12%
    Medium
    Revenue
    Annual Revenue Growth
    10-15%
    High
    Revenue
    Revenue
    INR2,600-2,700 crores
    High
    Sales
    Non-Ibuprofen export sales
    definitely increasing
    High

    Fuel cost normalization

    Q3 FY26
    CurrentINR7-8 crores impact in Q2 FY26
    TargetReduced by INR5-6 crores

    Why it matters

    Direct impact on EBITDA margins; normalization is expected to improve profitability in the current quarter.

    in this current quarter, we will achieve to power costs near to normal, and it will be reduced by INR5 crores to INR6 crores.

    How to verify

    key_financials.metrics[label='EBITDA Margin']

    Risks & concerns

    4
    RiskSeverity

    Elevated power and fuel costs due to Punjab floods

    Impacted Q2 profitability by INR7-8 crores, expected to normalize in Q3 FY26.Management acknowledged

    medium

    Subdued pricing in Chemicals segment

    Pricing remains under pressure, though volume recovery and cost optimization help offset.Management acknowledged

    medium

    High market competitiveness for new products like Sitagliptin

    Despite EDQM approval, commercial production is not being pushed due to price war and low profitability.Management acknowledged

    medium

    Pricing pressure in non-Ibuprofen APIs

    Ongoing for the last 3-4 quarters, but volume growth and diversification help mitigate.Management acknowledged

    medium

    Q&A highlights

    8

    “No, no, no. Actually, 62% is our ratio of Ibuprofen within pharma. And total pharma ratio is 59% and Chemical is 41%. 59% and 41%.”

    Clarifies the company's revenue composition, detailing the contribution of Ibuprofen within Pharma and the overall Pharma vs. Chemical split, which is crucial for understanding revenue drivers and diversification efforts.

    asked by Riya Jain

    3 min read7 chapters

    Detailed Narrative

    01

    Q2 FY26 Financial Performance Overview

    IOL Chemicals reported a robust Q2 FY26, with revenue from operations reaching INR567.5 crores, marking a 7.9% year-on-year growth. EBITDA increased significantly by 33.3% to INR64 crores, with margins expanding by 212 basis points to 11.1%. Profit after tax (PAT) also saw substantial growth of 56.7% to INR30 crores, improving the PAT margin to 5.2% from 3.6%. Post-tax cash profit grew 31.1% year-on-year to INR51.5 crores, highlighting strong operational cash generation.

    02

    Q2 Profitability Impact & Outlook

    The company experienced a slight sequential dip in profitability during Q2, primarily due to elevated power and fuel costs. This was attributed to heavy rains and floods in Punjab, which rendered basic raw materials like rice husk unusable, necessitating the use of costlier alternatives and electricity from the grid. This impact amounted to INR7-8 crores, affecting margins by approximately 1%. Management expects this effect to normalize in Q3 FY26, with power costs reducing by INR5-6 crores.

    03

    Segmental Performance and Product Mix

    The company's performance was driven by consistent execution across both its Pharmaceutical and Chemicals segments. In H1 FY26, Pharma constituted 59% of total revenue, with Ibuprofen accounting for 62% within Pharma and other APIs for 38%. Chemicals made up 41% of total revenue. The Pharmaceutical segment saw strong traction in non-Ibuprofen APIs like Clopidogrel and Pantoprazole. The Chemicals segment experienced steady volume recovery, though pricing remained subdued, with management focusing on cost optimization and product mix.

    04

    Paracetamol Capacity Expansion and Utilization

    The new paracetamol facility, which commenced operations in March 2025, is ramping up well. In Q2 FY26, the facility achieved 55-60% capacity utilization. Management targets to increase this utilization to approximately 65% by March end (FY26 end). This expansion from an earlier capacity of 3,600 metric tons to 11,800 metric tons is expected to contribute meaningfully to margin expansion as pricing trends improve and demand for IOL's paracetamol products gains traction.

    05

    Strategic Growth and Diversification

    IOL Chemicals is actively pursuing a strategy of diversification and shifting towards regulated markets to improve price realization and ensure stable demand. The company aims to achieve a 50% Ibuprofen and 50% other pharma products mix within its pharmaceutical portfolio in the coming years. Export sales for non-Ibuprofen APIs are expected to increase significantly in the upcoming quarters. The company's focus on R&D, innovation, and accelerated regulatory filings across Europe and other regulated markets supports this growth trajectory.

    06

    Capex Plans and Regulatory Updates

    The company has a capex plan of INR150-200 crores for both FY26 and FY27. In H1 FY26, approximately INR60 crores has already been utilized, with another INR100 crores planned for H2 FY26. This capex is allocated with 60% for growth (infra, land, new software, automation) and 40% for maintenance. Regulatory updates include a successful EU GMP inspection with only recommendations, and ongoing processes for Fenofibrate and Levetiracetam DMFs with FDA, awaiting further communication. The company also expects to secure all regulatory approvals for its acquired land parcel within two quarters.

    07

    Long-term Financial Targets

    IOL Chemicals is targeting an annual revenue growth of 10-15% and aims to achieve an EBITDA margin of 13-14% for H2 FY26, with an expected 1-2% increase in EBITDA margin annually. For FY27, the company projects revenue between INR2,600-2,700 crores and an EBITDA margin of 13-15%. These targets are underpinned by continued volume growth, cost efficiencies, and a strategic shift towards a diversified, export-driven portfolio in regulated markets.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.